Correlation of Immunological and Clinical Changes in Psoriasis Patients Treated with Tumour Necrosis Factor-Alpha (TNF-α) Blocking Biologic Drugs: One-Year Dynamic Observation
References
- Armstrong, A., Jarvis S., Boehncke, W. H., Rajagopalan, M. (2018). Patient perceptions of clear/almost clear skin in moderate-to-severe plaque psoriasis, results of the Clear About Psoriasis worldwide survey. J. Eur. Acad., Dermatol. Venereol., 32, 2200–2207.10.1111/jdv.1506529730888
- Bongiorno, M. R., Pistone, G., Doukaki, S., Arico, M. (2008). Adalimumab for treatment of moderate to severe psoriasis and psoriatic arthritis. Dermatol. Ther., 21, 15–20.10.1111/j.1529-8019.2008.00227.x18837728
- Caiazzo, G., Fabbrocini, G., Di Caprio, R. (2018). Psoriasis, cardiovascular events, and biologics, lights and shadows. Front Immunol., 9, 1–12.10.3389/fimmu.2018.01668609915930150978
- Chiricozzi, A., Romanelli, P., Volpe, E., Borsellino, G., Romanelli, M. (2018). Scanning the immunopathogenesis of psoriasis. Int. J. Mol. Sci., 19 (179), 1–31.10.3390/ijms19010179579612829316717
- Chiricozzi, A., Zangrilli, A., Bavetta, M., Bianchi L. (2017). Real-life 9-year expierence with adalimumab in psoriasis and psoriatic arthritis, results of a single-centre, retrospective study. J. Eur. Acad., Dermatol. Venereol., 31, 304–311.10.1111/jdv.1377127324646
- Constantin, M. M., Poenaru E., Constantin, T., Poenaru, C., Purcarea, V. L., Mateescu, B. R. (2014). Biological therapies in moderate and severe psoriasis, perspectives and certainties. J. Med. Life, 7, 15–17.
- Elyoussfi, S., Thomas, B. J., Ciurtin, C. (2016). Tailored treatment options for patients with psoriatic arthritis and psoriasis, review of established and new biologic and small molecile therapies. Rheumatol. Int., 36, 603–612.10.1007/s00296-016-3436-0483904626892034
- Gisondi, P., Cazzaniga, S., Chimenti. S. (2013a). Metabolic abnormalities associated with initation of systemic treatment for psoriasis, evidence from the Italian Psocare Registry. J. Eur. Acad., Dermatol. Venereol., 27, 30–41.10.1111/j.1468-3083.2012.04450.x22313340
- Gisondi, P., Tessari, G., Di Mercurio, M., Del Giglio, M, Girolomoni G. (2013b). The retention rate of systemic drugs in patients with chronic plaque psoriasis. Clin. Dermatol., 1, 8–14.
- Gniadecki, R., Leonardi, C. L, Gordon, K. B., Gu, Y. (2018). Long-term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis. J. Eur. Acad., Dermatol. Venereol., 32, 1297–1304.10.1111/jdv.1492629524255
- Gonzalez, J. M., Johnson F. R., McAteer, H., Posner, J., Mughal, F. (2017). Comparing preferences for outcomes of psoriasis treatments among patients and dermatologists in the U.K., results from a discrete- choice experiment. Brit. J. Dermatol., 176, 777–785.10.1111/bjd.1479827292093
- Hartmane I., Mikažāns I., Ivdra, I. (2016). Vidēji smagas un smagas gaitas psoriāzes klīniskās vadlīnijas [Clinical guidelines for moderate to severe psoriasis]. Rīga Stradiņš University. www.vmnvd.gov.lv (accessed 15.09.2021) (in Latvian).
- Jackson, J. M. (2007). TNF-α inhibitors. Dermatol. Ther., 20, 251–264.10.1111/j.1529-8019.2007.00138.x17970890
- Jacobi, A, Mahler, V., Schuler, G., Heri, M. (2006). Treatment of inflammatory dermatosi by tumor necrosis factor antagonists. J. Eur. Acad., Dermatol. Venereol., 20, 1171–1187.10.1111/j.1468-3083.2006.01733.x17062028
- Krueger, J. G. (2002). The immunologic basis for the treatment of psoriasis with new biologic agents. J. Amer. Acad. Dermatol., 46, 1–23.10.1067/mjd.2002.12056811756941
- Langewouters, A. M. G., van Erp, P. E. J., de Jong, E. M. G. J., van de Kerkhof, P. C. M. (2007). Lymphocyte subsets in peripheral blood of patients with moderate-to-severe versus mild plaque psoriasis. Arch. Dermatol. Res., 300, 107–113.10.1007/s00403-007-0819-9225465818157542
- Laurent, M. R., Panay, G., Shepherd, P. (1981). Circulating immune complexes, serum immunoglobulins, and acute phase proteīns in psoriasis and psoriatic arthritis. Ann. Rheum. Dis., 40, 66–69.10.1136/ard.40.1.6610006596970552
- Leonardi, C., Papp, K., Strober, B., Thaci, D., Warren, R. B. (2019). Comprehensive long-term safety of adalimumab from 18 clinical trials in adult patients with moderate-to-severe plaque psoriasis. Brit. J. Dermatol., 180, 76–85.10.1111/bjd.1708430169904
- Loos, A. M., Liu, A., Segel, C., Ollendorf, D. A. (2018). Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis, a systematic review and network meta-analysis. J. Amer. Acad. Dermatol., 79, 135–144.10.1016/j.jaad.2018.02.02729438757
- Mahil, S. K., Capon, F., Barker, J. N. (2016). Update on psoriasis immuno-pathogenesis and targeted immunotherapy. Semin. Immunopathol., 38, 11–27.10.1007/s00281-015-0539-8470657926573299
- Menter, A., Thaci, D., Papp, K., Wu, J. J., Bereswill, M. (2015). Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis. J. Amer. Acad. Dermatol., 73, 410–419.10.1016/j.jaad.2015.06.03826190240
- Nacionālais Veselības Dienests. Kompnsējamo zāļu saraksts [National Health Service. Reimbursement drug list]. http://www.vmnvd.gov.lv/lv/kompensejamie-medikamenti/kompensejamo-zalu-saraksts from 06/04/2020 (accessed 15 April 2020) (in Latvian).
- Nast, A., Boehncke, W. H., Mrowietz, U. (2012). S3-guidelines on the systemic treatment of psoriasis vulgaris. J. Dtsch. Dermatol. Ges., 10 (2), 1–95.
- Nast, A., Gisondi, P., Ormerod, A. D., Saiag, P., Smith, C., Puls, P. I., Arenberger, P., Barker, J., Dauden, E., de Jong, E. M. et al. (2015). European S3-guidelines on the systemic treatment of psoriasis vulgaris — Update 2015 — Short version — EDF in cooperation with EADV and IPC. J. Eur. Acad., Dermatol. Venereol., 29, 2277–2294.10.1111/jdv.1335426481193
- Oztürk, G., Erbaŗ D., Gelir, E., Gülekon, A., Imir, T. (2001). Natural killer cell activity, serum immunoglobulins, complement proteins, and zinc levels in patients with psoriasis vulgaris. Immunol. Invest., 30, 181–190.10.1081/IMM-100105063
- Papp, K., Crowley J., Ortonne, J. P. (2011). Adalimumab for moderate to severe chronic plaque psoriasis, efficacy and safety of retreatment and disease recurrence following withdrawal from therapy. Brit. J. Dermatol., 164, 434–441.10.1111/j.1365-2133.2010.10139.x21083543
- Papp, K., Menter, A., Poulin Y., Gu, Y., Sasso, E. H. (2013). Long-term outcomes of interrruption and retrearment vs. continuous therapy with adalimumab for psoriasis, subanalysis of REVEAL and the open-label extension study. J. Eur. Acad., Dermatol. Venereol., 27, 634–642.10.1111/j.1468-3083.2012.04515.x22429586
- Patel, T., Gordon, K. B. (2004). Adalimumab, efficacy and safety in psoriasis and rheumatoid arthritis. Dermatol. Ther., 17, 427–431.10.1111/j.1396-0296.2004.04045.x15379777
- Poulin, Y., Crowley, J. J., Langley, R. G. (2014). Effeicacy of adalimumab across subgoups of patients with moderate-to-severe chronic plaque psoriasis of the hands and/or feet, post hoc analysis of REACH. J. Eur. Acad., Dermatol. Venereol., 28, 882–890.10.1111/jdv.12198422902523790018
- Puig, L., Thorm, H., Mollon, P., Thian, H., Ramakrishina, G. S. (2017). Clear or almost ckear skin improves the quality of life in patients with moderate-ro-severe psoriasis, a systematic review and meta-analysis. J. Eur. Acad., Dermatol. Venereol., 31, 213–220.10.1111/jdv.1400727739123
- Rendon, A., Schake, K. (2019). Psoriasis pathogenesis and treatment. Int. J. Mol. Sci., 20, 1–28.10.3390/ijms20061475647162830909615
- Ronholt, K., Iversen, L. (2017). Old ans new biological therapies for psoriasis. Int. J. Mol. Sci., 18, 1–28.10.3390/ijms18112297571326729104241
- Sawyer, L. M., Cornic, L, Levin, L. A., Gibbons, C. (2019). Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis, a systematic review and network meta-analysis of PASI response. J. Eur. Acad., Dermatol. Venereol., 33, 355–366.10.1111/jdv.15277658778030289198
- Strober, B., Crowley, J., Langley, R. G., Gordon K. (2018). Systematic review of the real-world evidence of adalimumab safety in psoriasis registries. J. Eur. Acad., Dermatol. Venereol., 32, 2126–2133.10.1111/jdv.1520330067882
- Strober, B. E., Poulin, Y., Kerdel, F. A., Langley, R. G. (2010). Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy, efficacy and safety results from an open-label study. J. Amer. Acad. Dermatol., 64, 671–679.10.1016/j.jaad.2010.03.00921414495
- Takeshita, J., Grewal, S., Langan, S. M., Mehta, N. N. (2017). Psoriasis and comorbid diseases. J. Amer. Acad. Dermatol., 76, 377–390.10.1016/j.jaad.2016.07.064573165028212759
- Talamonti, M., Galluzo, M., Bernardini, N., Caldarola, G. (2018). Psoriasis area and severity index response in moderate-severe psoriatic patients switched to adalimumab, results from the OPPSA study. J. Amer. Acad. Dermatol., 32, 1737–1744.10.1111/jdv.1507729776016
- Thomas, J., Kupper, M., Batra, R., Jargosch, M., Atenhan, A. (2019). Is the humoral immunity dispensable for the pathogenesis of psoriasis? J. Amer. Acad. Dermatol., 33, 115–122.10.1111/jdv.1510129856508
- Toruniowa, B. (1992). Humoral indices of the inflammatory process in psoriasis. Pol. Tyg. Lek., 2, 44–45.
- Vaidya, T., Feldman, S. R., Kirk, J. (2015). Patient-centered approach to biologics in the treatment of psoriasis. J. Nat. Sci., 1, 1–7.
- Van Luming, P. P. M., Driessen, R. J. B., Roelofs-Thijssen, M. A. M. A. (2011). Relevance of laboratory investigations in monitoring patients with psoriasis on etanercept or adalimumab. Brit. J. Dermatol., 165, 375–382.10.1111/j.1365-2133.2011.10329.x21428975
- Van Luming, P. P. M., Lecluse, L. L. A., Driessen, R. J. B. (2010). Switching from etanercept to adalimumab is effective and safe, results in 30 patients with psoriasis primary failure, secondary failure or intolerance3 to etenercept. Brit. J. Dermatol., 163, 838–846.10.1111/j.1365-2133.2010.09950.x20649798
- Winterfield, L. S., Menter, A. (2004). Infliximab. Dermatol. Ther., 17, 409–426.10.1111/j.1396-0296.2004.04044.x15379776
- Wy, J. J., Joshi, A. A., Reddy, S. P., Batech, M. (2018). Anti-inflammatory therapy with tumor necrosis factor inhibitors is associated with reduced risk of major adverse cardiovascular events in psoriasis. J. Eur. Acad., Dermatol. Venereol., 32, 1320–1326.10.1111/jdv.1495129573294
- Zweegers, J., Otero, M. E. (2016). Effectiveness of biologic and conventional systemic therapies in adults with chronic plaque psoriasis in daily practoce, a systematic review. Acta Derm. Venerol., 96, 453–458.10.2340/00015555-227626537336
Language: English
Page range: 357 - 363
Submitted on: Jun 11, 2020
Accepted on: Jul 11, 2021
Published on: Nov 15, 2021
Published by: Latvian Academy of Sciences
In partnership with: Paradigm Publishing Services
Publication frequency: 6 issues per year
Related subjects:
© 2021 Ilona Hartmane, Iveta Ivdra, Ingmārs Mikažāns, Vanda Bondare-Ansberga, published by Latvian Academy of Sciences
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.